Exploring the Therapeutic Potential of BRCA1 and BRCA2 as Targets in Canine Oncology: A Comprehensive Review of Their Role in Cancer Development and Treatment
Preprint
- 20 January 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Tumor diseases represent a significant global health challenge, impacting both humans and companion animals, notably dogs. The parallels observed in the pathophysiology of cancer between humans and dogs underscore the importance of advancing comparative oncology and translational research methodologies. Moreover, dogs serve as valuable models for human cancer research due to shared environments, genetics, and treatment responses. Notably, breast cancer gene 1 (BRCA1) and breast cancer gene 2 (BRCA2), which are pivotal in human oncology, also influence the development and progression of canine tumors. The role of BRCA1 and BRCA2 in canine cancers remains underexplored, but their potential significance as therapeutic targets is strongly considered. This systematic review aims to broaden the discussion of BRCA1 and BRCA2 beyond mammary tumors, exploring their implications across various canine cancers. By emphasizing shared genetic underpinnings between species and advocating for a comparative approach, the review indicates the potential of BRCA genes as targets for innovative cancer therapies in dogs, contributing to advancements in both human and veterinary oncology.Keywords
All Related Versions
This publication has 77 references indexed in Scilit:
- PARP inhibitor combination therapyCritical Reviews in Oncology/Hematology, 2016
- An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor OlaparibTargeted Oncology, 2016
- Next-Generation Sequencing of the BRCA1 and BRCA2 Genes for the Genetic Diagnostics of Hereditary Breast and/or Ovarian CancerThe Journal of Molecular Diagnostics, 2015
- Genetic variations of BRCA1 and BRCA2 genes in dogs with mammary tumoursVeterinary Research Communications, 2013
- A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiationCancer Chemotherapy and Pharmacology, 2013
- Exploring the cancer genome in the era of next-generation sequencingFrontiers of Medicine, 2012
- ‘Putting our heads together’: insights into genomic conservation between human and canine intracranial tumorsJournal of Neuro-Oncology, 2009
- Incidence of and survival after mammary tumors in a population of over 80,000 insured female dogs in Sweden from 1995 to 2002Preventive Veterinary Medicine, 2005
- Roles of BRCA1 and its interacting proteinsBioEssays, 2000
- Identification of Rad51 alteration in patients with bilateral breast cancerJournal of Human Genetics, 2000